Patent EP0423484B1 successfully refreshed from Google Patents.
EP0423484B1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Tablet with sustained release
Assignee: PCD Polymere GmbH
•
Filing: 1990-09-12
•
Granted: 1993-11-03
•
Expires: 2010-09-12
Abstract
No abstract record available.
Inventors
- 👤 Brigitta Dr. Korsatko-Wabnegg
- 👤 Werner Dr. Korsatko
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 23:08
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
38 words
Pressing having sustained release of active compound for the oral or parenteral administration of medicaments, characterized in that the pressing contains at least one solid pharmaceutical active compound, polylactic acid and a homo- or copolymer of D(-)-3-hydroxybutyric acid.
Claim 2
Dependent Claim
19 words
Pressing according to Claim 1, characterized in that the polylactic acid has a molecular weight of 3,000 to 150,000.
Claim 3
Dependent Claim
23 words
Pressing according to Claim 1, characterized in that the homo- or copolymer of D(-)-3-hydroxybutyric acid has a molecular weight of 50,000 to 800,000.
Claim 4
Dependent Claim
33 words
Pressing according to one of Claims 1 to 3, characterized in that the polylactic acid and the homo- or copolymer of D(-)-3-hydroxybutyric acid are present in a weight ratio of 10:90 to 90:10.
Claim 5
Dependent Claim
26 words
Pressing according to one of Claims 1 to 4, characterized in that it contains 5 to 80 per cent by weight of solid pharmaceutical active compound.
Claim 6
Dependent Claim
79 words
Process for the production of a pressing having sustained release of active compound for the oral or parenteral administration of medicaments, characterized in that at least one solid pharmaceutical active compound in solid, dissolved or suspended form is combined and mixed with solid or dissolved polylactic acid and solid or dissolved homo- or copolymer of D(-)-3-hydroxybutyric acid, after which the solvent or diluent which may be present is evaporated, and the residue is optionally dried, optionally ground and compressed.
Claim 7
Dependent Claim
32 words
Process according to Claim 6, characterized in that at least one solid pharmaceutical active compound is mixed and compressed with solid polylactic acid and a solid homo- or copolymer of D(-)-3-hydroxybutyric acid.
Claim 8
Dependent Claim
41 words
Process according to Claim 6, characterized in that at least one solid pharmaceutical active compound or granules thereof are sprayed in a fluidized bed granulator with a solution of polylactic acid and homo- or copolymer of D(-)-3-hydroxybutyric acid, dried and compressed.
Claim 9
Dependent Claim
58 words
Process according to Claim 6, characterized in that at least one solid pharmaceutical active compound is suspended in a solvent for polylactic acid and for homo- or copolymer of D(-)-3-hydroxybutyric acid, mixed with dissolved polylactic acid and dissolved homo- or copolymer of D(-)-3-hydroxybutyric acid, after which the solvent is evaporated, and the residue is dried, ground and compressed.
Claim 10
Dependent Claim
61 words
Process according to Claim 6, characterized in that at least one solid pharmaceutical active compound is dissolved in a solvent for polylactic acid and for homo- or copolymer of D(-)-3-hydroxybutyric acid and dissolved polylactic acid and dissolved homo- or copolymer of D(-)-3-hydroxybutyric acid are added and mixed, after which the solvent is evaporated, and the residue is dried, ground and compressed.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.